Currently, there is an increased use of monoclonal antibodies in the context of the treatment of patients that suffer from cancer. In cooperation with a leading, internationally operating pharma company, this research group in Linz investigates the function of these innovative therapeutics on a molecular level.
|Short title||HS-AFM to study Fc:Fc interaction|
|Effective start/end date||01.09.2017 → 31.12.2022|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.